SOM230 increases in vivo sensitivity to gemcitabine of tumour xenograft (MIA PaCa‐2‐Luc cells and CAFs or human PDAC resection) A–CMIA PaCa‐2‐GLuc cells.

Slides:



Advertisements
Similar presentations
Effects of inhibiting inflammatory cell recruitment on fracture healing Treatment with CCR2 antagonist, INCB3344, led to impaired fracture healing compared.
Advertisements

Impact of triple combination of gemcitabine‐based chemoirradiation with anti‐PD‐L1 in the KPC tumor allograft Impact of triple combination of gemcitabine‐based.
Loss of Hdac3 impairs Ar signaling in mouse prostate tissues and has no effect on apoptosis Loss of Hdac3 impairs Ar signaling in mouse prostate tissues.
Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
TZD enhances cisplatin sensitivity through suppression of endotrophin‐mediated EMT, fibrosis and angiogenesis.A,B.Schematic diagram for allografts (A),
MiR‐10b* down‐regulates the expression of BUB1, PLK1 and CCNA2 proteins in breast cancer cell lines.A.SPIN‐ordered expression matrix of miR‐10b* and its.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
The HDAC3 inhibitor suppresses SPOP‐mutated prostate cancer cell growth The HDAC3 inhibitor suppresses SPOP‐mutated prostate cancer cell growth A22Rv1.
The gene encoding TP53INP1 is expressed in pancreatic endocrine cells A, B(A, B) Immunocytofluorescent staining of TP53INP1 (red) and insulin (green) in.
Treatment with p38γ/p38δ inhibitor shows antifungal effects in vivo
Reverse cholesterol transport is enhanced after systemic miR‐33 silencing.C57BL/6 mice (n = 7) were infused i.v. with 5 mpk scrambled or anti‐miR‐33 oligonucleotides.
AAV8‐hAAT‐FGF21 treatment improves liver fibrosis
The absence of COL6 in PyMT mice sensitizes tumours to cisplatin treatment.A.Eleven week old FP635/PyMT and FP635/PyMT/COL6−/− mice were given cisplatin.
Roles of systemic versus tumour SK1 in the regulation of local tumour growth and lung colonization/metastasis.A.Effects of siRNA‐mediated SK1 knockdown.
SPRY2 deficiency mediates androgen autonomous CRPC
ADAM8 maintains the aggressive phenotype of TNBC cells in 3D‐culture A–DCells were transfected with siRNAs as in Fig 2D and E for 24 h, and tested for.
Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.
Effects of SC144 on in vivo ovarian tumor.
Stat3 promotes lung fibrosis and collagen synthesis independent of Smad3.A.Masson's trichrome stained sections of lung from gp130wt (wt), Smad3−/− (Smad3−/−),
TFE3 prevents diet‐induced obesity and metabolic syndrome
Histological analysis of tumours in PyMT mice with different levels of endotrophin after chemotherapy.A.Endotrophin staining and quantification, showing.
SPRY2 deficiency mediates CRPC
NRP2 induces expression of GLI1. A,B
SPRY2 deficiency‐induced IL6 drives CRPC by elevating tumoral HSD3B1 and cholesterol levels SPRY2 deficiency‐induced IL6 drives CRPC by elevating tumoral.
Combination of OTX‐015 and PD does not induce overt toxicity
Stat3C/C mice are more prone to Th17 differentiation. A
SPRY2 deficiency‐induced SRB1 mediates CRPC
Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.
Molecular and clinical characterization of AAV2/8‐TBG‐h
Neutralizing endotrophin activity with monoclonal antibodies sensitizes tumours to cisplatin treatment.A.Pieces of tumours from PyMT mice were implanted.
USP9X and XIAP promote lymphoma growth and resistance to spindle poisons in vivo USP9X and XIAP promote lymphoma growth and resistance to spindle poisons.
The psoriatic phenotype of DKO
Association of AIM2, RIG‐I and NLRP3 inflammasomes with better survival in NPC patients.A.Overexpression of ASC, caspase‐1 and IL‐1β proteins as well as.
Effects of in vivo Nutlin‐3 treatment on CSC content of Numb− and Numb+ tumors Effects of in vivo Nutlin‐3 treatment on CSC content of Numb− and Numb+
IL‐23‐induced psoriasis‐like skin disease is ameliorated in IL‐23−/− mice IL‐23‐induced psoriasis‐like skin disease is ameliorated in IL‐23−/− mice ARepresentative.
Hccs downregulation induces apoptosome‐independent caspase‐9 activation in mitochondria.A–C.TUNEL assays on st30 embryos co‐injected with hccs‐MO and Apaf1‐MO.
Inhibition of NAMPT using the potent inhibitor FK866 sensitizes additional tumour cells to olaparib.A‐E.Sensitivity of the cell lines MDAMB468 (A), SUM149.
Enhancement of receptor endocytosis, as well as cellular apoptosis, may explain the cooperative anti‐tumor actions of 3×mAbs and osimertinib Enhancement.
In vivo efficacy of Olaparib in PTEN deficient xenografts.
GPRC5A is hypoxia/HIF‐induced in vivo
The HDAC3 inhibitor suppresses PTEN‐deficient prostate cancer growth
ADAM8 knockdown profoundly decreases orthotopic tumor formation, CTC spread and metastasis A–DStable ADAM8 KD (shA8) clones were characterized in vitro.
miR‐205 modulates tumor cell sensitivity to MET‐TKIs
P2X4R blockade increases autoimmune inflammation
Treatment with AZD5363 reduces the proportion of proliferating vascular endothelial cells and following RT, the influx of CD11b+ bone marrow‐derived cells.
T22‐GFP‐H6‐FdU‐induced depletion of CXCR4‐overexpressing cancer cells in tumor tissue T22‐GFP‐H6‐FdU‐induced depletion of CXCR4‐overexpressing cancer cells.
The MEK inhibitor CI‐1040 reverses thickening, fibrosis, and angiogenesis in the parietal peritoneum of Cav1−/− mice upon exposure to PD fluidWT or Cav1−/−
Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts.
SPRY2 deficiency‐induced IL6 drives CRPC by elevating tumoral HSD3B1 and cholesterol levels SPRY2 deficiency‐induced IL6 drives CRPC by elevating tumoral.
Sox2 is essential for SLG regeneration following radiation injury
GM1 decreases neuropathology and weight loss in R6/2 mice
Mpdz was localized proximal to the apical surface of CPECs
The oligoclonal antibody overcomes the C797S mutation‐mediated resistance to osimertinib The oligoclonal antibody overcomes the C797S mutation‐mediated.
Bevacizumab therapy leads to reduced vessel density and increased Ang‐2 expression Bevacizumab therapy leads to reduced vessel density and increased Ang‐2.
Limiting neutrophilic inflammation during active phase (ZT13) reduces MI damage Limiting neutrophilic inflammation during active phase (ZT13) reduces MI.
SEMA3C regulates prostate cancer cell growth
Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.
PTENP1 sensitizes renal cancer cells to chemotherapy.
Silencing hOGG1 triggers caspase-3 and caspase-7 activation in response to H2O2 in GM00637 cells. Silencing hOGG1 triggers caspase-3 and caspase-7 activation.
Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.
In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.
Quercetin induces apoptosis in P39 xenografts.
Depletion of UCP1 and Myf5 population reduced xenograft growth.
GA reduces the growth of Caki-1 tumor xenografts.
In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,
Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.
Effect of CDV on human SF7796 xenografts in vivo.
Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.
Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.
DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.
Presentation transcript:

SOM230 increases in vivo sensitivity to gemcitabine of tumour xenograft (MIA PaCa‐2‐Luc cells and CAFs or human PDAC resection) A–CMIA PaCa‐2‐GLuc cells were injected with or without CAFs into the pancreas of nude mice. SOM230 increases in vivo sensitivity to gemcitabine of tumour xenograft (MIA PaCa‐2‐Luc cells and CAFs or human PDAC resection) A–CMIA PaCa‐2‐GLuc cells were injected with or without CAFs into the pancreas of nude mice. Mice were treated with each indicated treatment (SOM230‐LAR at day 7 and gemcitabine at days 7, 10, 14 and 17), and the plasmatic luciferase activity was measured (mean ± SD) at days 7, 14 and 21 (n = 5) (P = 0.003 for gemcitabine + SOM230LAR versus untreated) (A). Tumours were excised, photographed (scale bars are 1 cm) (B), weighted (P = 0.0008) (C) and paraffin‐embedded for immunohistofluorescence analyses using an anti‐cleaved caspase‐3 antibody (E).DHuman tumours were subcutaneously xenografted in nude mice and tumour volumes (mean ± SD) measured (at day 37, P = 0.0009 for gemcitabine + SOM230LAR versus untreated and P = 0.021 for gemcitabine + SOM230LAR versus gemcitabine). Mice were treated with the indicated treatments (SOM230‐LAR at days 3 and 31, and gemcitabine at day 3 and twice a week thereafter).E, FTumours excised from mice as in (A‐C) were paraffin‐embedded for immunohistofluorescence analyses using an anti‐cleaved caspase‐3 antibody (scale bar = 100 μm) (E). Cleaved caspase‐3 quantification was performed by counting the mean number of positive cells per field in five independent tumours (mean ± SD) (F) (*P = 0.036, **P = 0.009).G, HTumours excised from mice as in (D) were paraffin‐embedded for immunohistofluorescence analyses using an anti‐cleaved caspase‐3 antibody (scale bar = 100 μm) (G). Cleaved caspase‐3 quantification was performed by counting the mean number of positive cells per field in five independent tumours (mean ± SD) (H) (*P = 0.027).Data information: * treated versus untreated xenograft. # SOM230‐LAR + gemcitabine‐treated versus gemcitabine‐treated xenograft. *P < 0.05; **P < 0.01; ***P < 0.001. Camille Duluc et al. EMBO Mol Med. 2015;7:735-753 © as stated in the article, figure or figure legend